person · Reporting owner

THERO JOHN F

Disclosed activity across 4 companies

Tapewire entity: 94414
SEC CIK: 0001199637

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cyteir Therapeutics, Inc.CYT · Entity 92707	Director	February 08, 2024	February 12, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cyteir Therapeutics, Inc.

Report date February 08, 2024 · Filed February 12, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	22,828	Reported balance After 2024-02-08 transaction · row 1 1 source row Row 1 · 2024-02-08 · Exercise / conversion · Acquired 12,828 · Balance 22,828
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03	Direct	0	Reported balance After 2024-02-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-02-08 · Exercise / conversion · Disposed 12,828 · Balance 0

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMARIN CORP PLC\UK

Report date July 30, 2021 · Filed August 04, 2021

Section 16 reporting ended · disclosed 2021-08-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	3,243,148	Reported balance After 2021-07-30 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-07-30 · Exercise / conversion · Acquired 6,736 · Balance 3,243,148 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021. F3: Not applicable.
Ordinary SharesSEC Table I · non-derivative	Direct	3,249,884	Reported balance After 2021-07-30 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2021-07-30 · Exercise / conversion · Acquired 6,736 · Balance 3,249,884 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021. F3: Not applicable.
Ordinary SharesSEC Table I · non-derivative	Direct	3,263,356	Reported balance After 2021-07-30 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2021-07-30 · Exercise / conversion · Acquired 13,472 · Balance 3,263,356 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021. F3: Not applicable.
Ordinary SharesSEC Table I · non-derivative	Direct	3,252,752	Reported balance After 2021-07-30 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2021-07-30 · Tax withholding · Disposed 10,604 · Balance 3,252,752 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F5: Please see the section titled "Remarks" below for additional information.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	6,736	Reported balance After 2021-07-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-30 · Exercise / conversion · Disposed 6,736 · Balance 6,736 F6: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021. F3: Not applicable. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	6,736	Reported balance After 2021-07-30 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-07-30 · Exercise / conversion · Disposed 6,736 · Balance 6,736 F6: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021. F3: Not applicable. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	13,472	Reported balance After 2021-07-30 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-07-30 · Exercise / conversion · Disposed 13,472 · Balance 13,472 F6: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021. F3: Not applicable. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: As previously reported on February 27, 2020 and March 1, 2021, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirty-fifth vesting event occurred on July 30, 2021.

F3: Not applicable.

F4: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.

F5: Please see the section titled "Remarks" below for additional information.

F6: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.

CHIASMA, INC

Report date August 05, 2021 · Filed August 05, 2021

Section 16 reporting ended · disclosed 2021-08-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.65	Direct	Reported balance After 2021-08-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-08-05 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.14	Direct	Reported balance After 2021-08-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-08-05 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35	Direct	Reported balance After 2021-08-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45	Direct	Reported balance After 2021-08-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.98	Direct	Reported balance After 2021-08-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.81	Direct	Reported balance After 2021-08-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time").

F2: At the Effective Time, each option to purchase Shares (each a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.

CinCor Pharma, Inc.

Report date February 24, 2023 · Filed February 24, 2023

Section 16 reporting ended · disclosed 2023-02-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.82 · Expires 2031-06-17	Direct	0	Reported balance After 2023-02-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-02-24 · Disposition to issuer · Disposed 36,324 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2031-12-09	Direct	0	Reported balance After 2023-02-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-02-24 · Disposition to issuer · Disposed 58,823 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 26, 2021 Filed Mar 2, 2021 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,736	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-21-001705 · primarydocument.xml · derivative · entry 11 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,416 Underlying: Ordinary Shares · 6,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F5 · derivative.exercise_date: As previously reported on February 27, 2020 and herewith in Footnote 2, on May 15, 2017, the Reporting Person was granted 970,000 RSUs under the Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirtieth vesting event occurred on February 26, 2021. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 26, 2021 Filed Mar 2, 2021 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,736	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-21-001705 · primarydocument.xml · derivative · entry 10 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,416 Underlying: Ordinary Shares · 6,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F5 · derivative.exercise_date: As previously reported on February 27, 2020 and herewith in Footnote 2, on May 15, 2017, the Reporting Person was granted 970,000 RSUs under the Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirtieth vesting event occurred on February 26, 2021. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 26, 2021 Filed Mar 2, 2021 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	23,361	$6.74	$157,453.14	Disclosure SEC source: 0001562180-21-001705 · primarydocument.xml · nonDerivative · entry 8 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,171,052 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F7 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
February 26, 2021 Filed Mar 2, 2021 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	59,367	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-001705 · primarydocument.xml · nonDerivative · entry 7 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,194,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F6 · kind: On March 2, 2020, the Reporting Person was granted 178,100 RSUs under the Plan. These RSUs vest in three equal installments on each of February 28, 2021, February 28, 2022 and February 28, 2023. The first vesting event occurred on February 26, 2021. F3 · price: Not applicable. Read SEC document
February 26, 2021 Filed Mar 2, 2021 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	10,604	$6.74	$71,470.96	Disclosure SEC source: 0001562180-21-001705 · primarydocument.xml · nonDerivative · entry 6 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135,046 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. Read SEC document
February 26, 2021 Filed Mar 2, 2021 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	13,472	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-001705 · primarydocument.xml · nonDerivative · entry 5 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,145,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: As previously reported on February 27, 2020 and herewith in Footnote 2, on May 15, 2017, the Reporting Person was granted 970,000 RSUs under the Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirtieth vesting event occurred on February 26, 2021. F3 · price: Not applicable. Read SEC document
February 26, 2021 Filed Mar 2, 2021 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,736	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-001705 · primarydocument.xml · nonDerivative · entry 4 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,132,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: As previously reported on February 27, 2020 and herewith in Footnote 2, on May 15, 2017, the Reporting Person was granted 970,000 RSUs under the Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirtieth vesting event occurred on February 26, 2021. F3 · price: Not applicable. Read SEC document
February 26, 2021 Filed Mar 2, 2021 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,736	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-001705 · primarydocument.xml · nonDerivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: As previously reported on February 27, 2020 and herewith in Footnote 2, on May 15, 2017, the Reporting Person was granted 970,000 RSUs under the Plan, of which the performance criteria related to two tranches representing 25% of the total award each was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million and of which the performance criteria related to one tranche representing 50% of the total award was deemed achieved on February 25, 2021 pursuant to reporting of audited net product revenues for 2020 exceeding $500 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The thirtieth vesting event occurred on February 26, 2021. F3 · price: Not applicable. Read SEC document
February 25, 2021 Filed Mar 2, 2021 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	390,696	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-21-001705 · primarydocument.xml · derivative · entry 9 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,304 Underlying: Ordinary Shares · 390,696 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported, on May 15 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs consist of 3 tranches representing 25%, 25% and 50% of the total award. Each tranche vests ratably over 36 months beginning Sept. 30 2018 subject to achievement of certain prespecified performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. On Feb. 25 2021, pursuant to reporting of audited net total revenue for 2020 exceeding $500 million, the performance criteria related to the 50% tranche was deemed achieved, resulting in the vesting of 390,696 RSUs (29 of 36 months' worth). The remaining RSUs in this tranche will continue to vest over 7 monthly installments, the first of which vested Feb. 26 2021. The performance criteria related to both 25% tranches were previously deemed achieved (see Footnote 5). F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 25, 2021 Filed Mar 2, 2021 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	153,739	$7.30	$1,122,294.70	Disclosure SEC source: 0001562180-21-001705 · primarydocument.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,118,706 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. Read SEC document
February 25, 2021 Filed Mar 2, 2021 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	390,696	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-001705 · primarydocument.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,272,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: As previously reported, on May 15 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs consist of 3 tranches representing 25%, 25% and 50% of the total award. Each tranche vests ratably over 36 months beginning Sept. 30 2018 subject to achievement of certain prespecified performance criteria and continued service of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. On Feb. 25 2021, pursuant to reporting of audited net total revenue for 2020 exceeding $500 million, the performance criteria related to the 50% tranche was deemed achieved, resulting in the vesting of 390,696 RSUs (29 of 36 months' worth). The remaining RSUs in this tranche will continue to vest over 7 monthly installments, the first of which vested Feb. 26 2021. The performance criteria related to both 25% tranches were previously deemed achieved (see Footnote 5). F3 · price: Not applicable. Read SEC document
January 29, 2021 Filed Jan 30, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,736	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-21-000645 · primarydocument.xml · derivative · entry 10 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,152 Underlying: Ordinary Shares · 6,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F6 · derivative.exercise_date: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 RSUs under the Plan, of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-ninth vesting event occurred on January 29, 2021. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 29, 2021 Filed Jan 30, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,736	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-21-000645 · primarydocument.xml · derivative · entry 9 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,152 Underlying: Ordinary Shares · 6,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F6 · derivative.exercise_date: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 RSUs under the Plan, of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-ninth vesting event occurred on January 29, 2021. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 29, 2021 Filed Jan 30, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	72,033	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-21-000645 · primarydocument.xml · derivative · entry 8 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,033 Underlying: Ordinary Shares · 72,033 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F4 · derivative.exercise_date: On February 1, 2019, the Reporting Person was granted 216,100 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2020, January 31, 2021, and January 31, 2022. The second vesting event occurred on January 29, 2021. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 29, 2021 Filed Jan 30, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	123,666	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-21-000645 · primarydocument.xml · derivative · entry 7 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 123,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: On February 1, 2018, the Reporting Person was granted 371,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2019, January 31, 2020, and January 31, 2021. The third and final vesting event occurred on January 29, 2021. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 29, 2021 Filed Jan 30, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	5,302	$7.50	$39,765.00	Disclosure SEC source: 0001562180-21-000645 · primarydocument.xml · nonDerivative · entry 6 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,881,749 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F7 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
January 29, 2021 Filed Jan 30, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,736	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-000645 · primarydocument.xml · nonDerivative · entry 5 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,887,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F6 · kind: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 RSUs under the Plan, of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-ninth vesting event occurred on January 29, 2021. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · price: Not applicable. Read SEC document
January 29, 2021 Filed Jan 30, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,736	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-000645 · primarydocument.xml · nonDerivative · entry 4 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,880,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F6 · kind: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 RSUs under the Plan, of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-ninth vesting event occurred on January 29, 2021. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · price: Not applicable. Read SEC document
January 29, 2021 Filed Jan 30, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	77,460	$7.50	$580,950.00	Disclosure SEC source: 0001562180-21-000645 · primarydocument.xml · nonDerivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,873,579 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. Read SEC document
January 29, 2021 Filed Jan 30, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	72,033	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-000645 · primarydocument.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,951,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · kind: On February 1, 2019, the Reporting Person was granted 216,100 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2020, January 31, 2021, and January 31, 2022. The second vesting event occurred on January 29, 2021. F3 · price: Not applicable. Read SEC document
January 29, 2021 Filed Jan 30, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	123,666	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-000645 · primarydocument.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,879,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: On February 1, 2018, the Reporting Person was granted 371,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2019, January 31, 2020, and January 31, 2021. The third and final vesting event occurred on January 29, 2021. F3 · price: Not applicable. Read SEC document
January 04, 2021 Filed Jan 6, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantRestricted Stock Units · Derivative	574,100	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-21-000125 · primarydocument.xml · derivative · entry 7 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574,100 Underlying: Ordinary Shares · 574,100 shares Expires not disclosed F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F8 · derivative.exercise_date: On January 4, 2021, the Reporting Person was granted 574,100 RSUs under the 2020 Plan. These RSUs vest in three equal installments on each of December 31, 2021, December 31, 2022 and December 31, 2023. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 04, 2021 Filed Jan 6, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantStock Option (Right to Buy) · Derivative	775,000	$0.00 Strike: $5.03	$0.00	Disclosure SEC source: 0001562180-21-000125 · primarydocument.xml · derivative · entry 6 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,000 Underlying: Ordinary Shares · 775,000 shares Expires 2031-01-04 F7 · derivative.exercise_date: On January 4, 2021, the Reporting Person was granted an option to purchase 775,000 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "2020 Plan" and, together with the 2011 Plan, the "Plans"). The shares subject to this option shall vest and become exercisable over four years, with 25% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 12 calendar quarters on the last day of each March, June, September and December. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
December 31, 2020 Filed Jan 6, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,736	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-21-000125 · primarydocument.xml · derivative · entry 5 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,888 Underlying: Ordinary Shares · 6,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "2011 Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-eighth vesting event occurred on December 31, 2020. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
December 31, 2020 Filed Jan 6, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,736	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-21-000125 · primarydocument.xml · derivative · entry 4 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,888 Underlying: Ordinary Shares · 6,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "2011 Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-eighth vesting event occurred on December 31, 2020. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
December 31, 2020 Filed Jan 6, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	5,302	$5.23	$27,729.46	Disclosure SEC source: 0001562180-21-000125 · primarydocument.xml · nonDerivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,755,340 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F5 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
December 31, 2020 Filed Jan 6, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,736	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-000125 · primarydocument.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,760,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "2011 Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-eighth vesting event occurred on December 31, 2020. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · price: Not applicable. Read SEC document
December 31, 2020 Filed Jan 6, 2021 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,736	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-21-000125 · primarydocument.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,753,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "2011 Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-eighth vesting event occurred on December 31, 2020. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · price: Not applicable. Read SEC document
November 30, 2020 Filed Dec 3, 2020 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,736	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-20-007027 · primarydocument.xml · derivative · entry 5 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,624 Underlying: Ordinary Shares · 6,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-seventh vesting event occurred on November 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
November 30, 2020 Filed Dec 3, 2020 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,736	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-20-007027 · primarydocument.xml · derivative · entry 4 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,624 Underlying: Ordinary Shares · 6,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-seventh vesting event occurred on November 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
November 30, 2020 Filed Dec 3, 2020 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	5,302	$4.60	$24,389.20	Disclosure SEC source: 0001562180-20-007027 · primarydocument.xml · nonDerivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,747,170 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F5 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
November 30, 2020 Filed Dec 3, 2020 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,736	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-20-007027 · primarydocument.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,752,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-seventh vesting event occurred on November 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · price: Not applicable. Read SEC document
November 30, 2020 Filed Dec 3, 2020 01:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,736	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-20-007027 · primarydocument.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,745,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-seventh vesting event occurred on November 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been formally deemed achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · price: Not applicable. Read SEC document
November 11, 2020 Filed Nov 13, 2020 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	413,565	$4.07	$1,681,183.08	Disclosure SEC source: 0001562180-20-006684 · primarydocument.xml · nonDerivative · entry 4 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,739,000 F1 · security: Acquisitions reported in this Form 4 pertain to exercises of stock options scheduled to expire on Nov. 10, 2020. In the first of the reported acquisitions, dated Nov. 9, 2020, 134,739 shares were acquired for $500,000, in cash, covering the exercise price of the stock options and the related taxes. The second acquisition, dated Nov. 10, 2020, involved shares acquired by the Reporting Person for cash offset by proceeds from sales of a portion of the acquired shares with the net remaining shares, after paying for cost for this second acquisition including taxes, added to the holdings of the Reporting Person. The result of these transactions, for cash and other consideration paid, was a net increase in shares held by the Reporting Person of 182,595 shares. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.01 to $4.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
November 10, 2020 Filed Nov 13, 2020 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	615,261	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0001562180-20-006684 · primarydocument.xml · derivative · entry 6 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 615,261 shares Expires 2020-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
November 10, 2020 Filed Nov 13, 2020 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	153,840	$4.13	$635,974.56	Disclosure SEC source: 0001562180-20-006684 · primarydocument.xml · nonDerivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,152,565 F1 · security: Acquisitions reported in this Form 4 pertain to exercises of stock options scheduled to expire on Nov. 10, 2020. In the first of the reported acquisitions, dated Nov. 9, 2020, 134,739 shares were acquired for $500,000, in cash, covering the exercise price of the stock options and the related taxes. The second acquisition, dated Nov. 10, 2020, involved shares acquired by the Reporting Person for cash offset by proceeds from sales of a portion of the acquired shares with the net remaining shares, after paying for cost for this second acquisition including taxes, added to the holdings of the Reporting Person. The result of these transactions, for cash and other consideration paid, was a net increase in shares held by the Reporting Person of 182,595 shares. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.11 to $4.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 10, 2020 Filed Nov 13, 2020 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	615,261	$3.40	$2,091,887.40	Disclosure SEC source: 0001562180-20-006684 · primarydocument.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,306,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Acquisitions reported in this Form 4 pertain to exercises of stock options scheduled to expire on Nov. 10, 2020. In the first of the reported acquisitions, dated Nov. 9, 2020, 134,739 shares were acquired for $500,000, in cash, covering the exercise price of the stock options and the related taxes. The second acquisition, dated Nov. 10, 2020, involved shares acquired by the Reporting Person for cash offset by proceeds from sales of a portion of the acquired shares with the net remaining shares, after paying for cost for this second acquisition including taxes, added to the holdings of the Reporting Person. The result of these transactions, for cash and other consideration paid, was a net increase in shares held by the Reporting Person of 182,595 shares. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
November 09, 2020 Filed Nov 13, 2020 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	134,739	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0001562180-20-006684 · primarydocument.xml · derivative · entry 5 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,261 Underlying: Ordinary Shares · 134,739 shares Expires 2020-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
November 09, 2020 Filed Nov 13, 2020 01:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	134,739	$3.40	$458,112.60	Disclosure SEC source: 0001562180-20-006684 · primarydocument.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,691,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Acquisitions reported in this Form 4 pertain to exercises of stock options scheduled to expire on Nov. 10, 2020. In the first of the reported acquisitions, dated Nov. 9, 2020, 134,739 shares were acquired for $500,000, in cash, covering the exercise price of the stock options and the related taxes. The second acquisition, dated Nov. 10, 2020, involved shares acquired by the Reporting Person for cash offset by proceeds from sales of a portion of the acquired shares with the net remaining shares, after paying for cost for this second acquisition including taxes, added to the holdings of the Reporting Person. The result of these transactions, for cash and other consideration paid, was a net increase in shares held by the Reporting Person of 182,595 shares. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
October 30, 2020 Filed Nov 4, 2020 01:23 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,736	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-20-006527 · primarydocument.xml · derivative · entry 4 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,360 Underlying: Ordinary Shares · 6,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-sixth vesting event occurred on October 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
October 30, 2020 Filed Nov 4, 2020 01:23 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,736	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-20-006527 · primarydocument.xml · derivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,360 Underlying: Ordinary Shares · 6,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-sixth vesting event occurred on October 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
October 30, 2020 Filed Nov 4, 2020 01:23 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,736	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-20-006527 · primarydocument.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,556,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-sixth vesting event occurred on October 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · price: Not applicable. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
October 30, 2020 Filed Nov 4, 2020 01:23 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,736	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-20-006527 · primarydocument.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,549,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-sixth vesting event occurred on October 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · price: Not applicable. Read SEC document
September 30, 2020 Filed Oct 3, 2020 00:03 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,737	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-20-006248 · primarydocument.xml · derivative · entry 4 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,096 Underlying: Ordinary Shares · 6,737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-fifth vesting event occurred on September 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
September 30, 2020 Filed Oct 3, 2020 00:03 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,737	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-20-006248 · primarydocument.xml · derivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,096 Underlying: Ordinary Shares · 6,737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-fifth vesting event occurred on September 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
September 30, 2020 Filed Oct 3, 2020 00:03 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,737	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-20-006248 · primarydocument.xml · nonDerivative · entry 2 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,542,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-fifth vesting event occurred on September 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · price: Not applicable. F4 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
September 30, 2020 Filed Oct 3, 2020 00:03 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	6,737	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-20-006248 · primarydocument.xml · nonDerivative · entry 1 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,536,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-fifth vesting event occurred on September 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · price: Not applicable. Read SEC document
August 31, 2020 Filed Sep 3, 2020 00:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,736	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-20-005777 · primarydocument.xml · derivative · entry 5 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,833 Underlying: Ordinary Shares · 6,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-fourth vesting event occurred on August 31, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
August 31, 2020 Filed Sep 3, 2020 00:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionRestricted Stock Units · Derivative	6,736	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-20-005777 · primarydocument.xml · derivative · entry 4 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,833 Underlying: Ordinary Shares · 6,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F2 · derivative.exercise_date: As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-fourth vesting event occurred on August 31, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
August 31, 2020 Filed Sep 3, 2020 00:01 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Tax withholdingOrdinary Shares	5,302	$7.36	$39,022.72	Disclosure SEC source: 0001562180-20-005777 · primarydocument.xml · nonDerivative · entry 3 THERO JOHN F · CIK 0001199637 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,529,459 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F5 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.